Download PDF
Int J Angiol 2017; 26(02): 102-108
DOI: 10.1055/s-0036-1593827
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Interaction of Serum Phosphate with Age as Predictors of Cardiovascular Risk Scores in Stable Renal Transplant Recipients

Jillian Kerry
1   College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
,
Holly Mansell
2   College of Pharmacy and and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
,
Hamdi Elmoselhi
3   Saskatchewan Transplant Program, Saskatoon Health Region, Saskatoon, Saskatchewan, Canada
,
Mike Moser
1   College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
3   Saskatchewan Transplant Program, Saskatoon Health Region, Saskatoon, Saskatchewan, Canada
,
Ahmed Shoker
3   Saskatchewan Transplant Program, Saskatoon Health Region, Saskatoon, Saskatchewan, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
12 December 2016 (online)

    Permissions and Reprints

Abstract

We calculated rate of changes in the cardiovascular risk calculator for renal transplant recipients (CRCRTR) major adverse cardiac events (MACE) in clinically stable renal transplant recipients (RTRs) to identify covariables that associate with fast cardiovascular (CV) risk progression. CRCRTR-MACE scores were calculated on 139 patients in 2011 and 2014. Score changes above and below median changes in scores were labeled fast or slow CV risk progression. Multivariate analysis (MVA) was performed to identify variables significant to percentage changes in scores. Receiver-operating characteristic (ROC) analysis was performed to define sensitivity and specificity of factors significant to fast score progression. Follow-up was 2.61 (2.02–4.47) years. Slow and fast progressions were present in 50.4 and 49.6% of patients, with a median change of 25.8% (− 92.1 to 1,444.7%). MVA showed percentage changes in age and serum phosphate were the only significant variables impacting fast progression in scores. ROC showed 2011 serum phosphate of 1.15 mmol/L to predict fast progression (area under the curve [AUC] of 0.628, p > 0.0126). Age older than 45 years combined with 2011 serum phosphate above 1.15 mmol/L had a significant AUC of 0.781, p < 0.0010 interleukin (IL)-1A and IL-28A were significant associates with serum phosphate above 1.1 mmol/L in the MVA. Changes in CV risk in RTR over time are highly variable. Serum phosphate, even within upper normal levels, predicts worsening of CV risk scores in stable RTR.

Keywords

renal function - cardiovascular risk factors - cardiovascular disease - glomerular filtration rate - renal transplant - cardiovascular risk calculator for renal transplant recipients - phosphorous
 

  • References

  • 1 US Renal Data System. USRDS 2014 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013. Available at: https://www.usrds.org/2014/view/ . Accessed on April 28, 2017
    Google Scholar
  • 2 Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 (12, Suppl): S16-S23
    PubMedGoogle Scholar
  • 3 Gill S. Cardiovascular disease in transplant recipients and future treatment strategies. Clin J Am Soc Nephrol 2008; 3: 29-37
    CrossrefPubMedGoogle Scholar
  • 4 Soveri I, Holme I, Holdaas H, Budde K, Jardine AG, Fellström B. A cardiovascular risk calculator for renal transplant recipients. Transplantation 2012; 94 (1) 57-62
    PubMedGoogle Scholar
  • 5 Mansell H, Rosaasen N, Dean J, Shoker A. Evidence of enhanced systemic inflammation in stable kidney transplant recipients with low Framingham risk scores. Clin Transplant 2013; 27 (4) E391-E399
    CrossrefPubMedGoogle Scholar
  • 6 Anderson TJ, Grégoire J, Hegele RA , et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013; 29 (2) 151-167
    CrossrefPubMedGoogle Scholar
  • 7 Sarnak MJ, Levey AS, Schoolwerth AC , et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42 (5) 1050-1065
    CrossrefPubMedGoogle Scholar
  • 8 Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004; 66 (1) 441-447
    CrossrefPubMedGoogle Scholar
  • 9 Kiberd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol 2008; 3 (3) 822-828
    CrossrefPubMedGoogle Scholar
  • 10 Kasiske BL, Anjum S, Shah R , et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43 (6) 1071-1081
    CrossrefPubMedGoogle Scholar
  • 11 Ramezani M, Einollahi B, Ahmadzad-Asl M , et al. Hyperlipidemia after renal transplantation and its relation to graft and patient survival. Transplant Proc 2007; 39 (4) 1044-1047
    CrossrefPubMedGoogle Scholar
  • 12 Clark WF, Macnab JJ, Sontrop JM , et al. Dipstick proteinuria as a screening strategy to identify rapid renal decline. J Am Soc Nephrol 2011; 22 (9) 1729-1736
    CrossrefPubMedGoogle Scholar
  • 13 Nauta FL, Scheven L, Meijer E , et al. Glomerular and tubular damage markers in individuals with progressive albuminuria. Clin J Am Soc Nephrol 2013; 8 (7) 1106-1114
    CrossrefPubMedGoogle Scholar
  • 14 Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75 (8) 1291-1295
    CrossrefPubMedGoogle Scholar
  • 15 Weiner DE, Carpenter MA, Levey AS , et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant 2012; 12 (9) 2437-2445
    CrossrefPubMedGoogle Scholar
  • 16 Rusanov A, Weiskopf NG, Wang S, Weng C. Hidden in plain sight: bias towards sick patients when sampling patients with sufficient electronic health record data for research. BMC Med Inform Decis Mak 2014; 14: 51
    CrossrefPubMedGoogle Scholar
  • 17 Manghat P, Sodi R, Swaminathan R. Phosphate homeostasis and disorders. Ann Clin Biochem 2014; 51 (Pt 6): 631-656
    CrossrefPubMedGoogle Scholar
  • 18 Wojcicki JM. Hyperphosphatemia is associated with anemia in adults without chronic kidney disease: results from the National Health and Nutrition Examination Survey (NHANES): 2005-2010. BMC Nephrol 2013; 14: 178
    CrossrefPubMedGoogle Scholar
  • 19 Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G ; Cholesterol And Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112 (17) 2627-2633
    CrossrefPubMedGoogle Scholar
  • 20 McGovern AP, de Lusignan S, van Vlymen J , et al. Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study. PLoS One 2013; 8 (9) e74996
    CrossrefPubMedGoogle Scholar
  • 21 Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20 (2) 397-404
    CrossrefPubMedGoogle Scholar
  • 22 Shroff R. Phosphate is a vascular toxin. Pediatr Nephrol 2013; 28 (4) 583-593
    CrossrefPubMedGoogle Scholar
  • 23 Voormolen N, Noordzij M, Grootendorst DC , et al; PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22 (10) 2909-2916
    CrossrefPubMedGoogle Scholar
  • 24 Park KS, Chang JW, Kim TY , et al. Lower concentrations of serum phosphorus within the normal range could be associated with less calcification of the coronary artery in Koreans with normal renal function. Am J Clin Nutr 2011; 94 (6) 1465-1470
    CrossrefPubMedGoogle Scholar
  • 25 Foley RN. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol 2009; 4 (6) 1136-1139
    CrossrefPubMedGoogle Scholar
  • 26 Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003; 14 (9) (Suppl. 04) S300-S304
    CrossrefPubMedGoogle Scholar
  • 27 Sim JJ, Bhandari SK, Smith N , et al. Phosphorus and risk of renal failure in subjects with normal renal function. Am J Med 2013; 126 (4) 311-318
    CrossrefPubMedGoogle Scholar
  • 28 Nadkarni GN, Uribarri J. Phosphorus and the kidney: what is known and what is needed. Adv Nutr 2014; 5 (1) 98-103
    CrossrefPubMedGoogle Scholar
  • 29 Takeda E, Taketani Y, Sawada N, Sato T, Yamamoto H. The regulation and function of phosphate in the human body. Biofactors 2004; 21 (1–4): 345-355
    CrossrefPubMedGoogle Scholar
  • 30 Isakova T, Gutiérrez OM, Smith K , et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26 (2) 584-591
    CrossrefPubMedGoogle Scholar
  • 31 Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91: 3144-3149
    CrossrefPubMedGoogle Scholar
  • 32 Portale AA, Halloran BP, Morris Jr RC. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989; 83 (5) 1494-1499
    CrossrefPubMedGoogle Scholar
  • 33 Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90 (3) 1519-1524
    CrossrefPubMedGoogle Scholar
  • 34 Bellasi A, Mandreoli M, Baldrati L , et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol 2011; 6 (4) 883-891
    CrossrefPubMedGoogle Scholar
  • 35 Chung HY, Cesari M, Anton S , et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev 2009; 8 (1) 18-30
    CrossrefPubMedGoogle Scholar
  • 36 Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 2012; 111 (2) 245-259
    CrossrefPubMedGoogle Scholar